![]() ![]() But gene therapy and gene editing have significant limitations in the modifications they can make to the genome, the cells they can affect, and how they are manufactured and delivered to cells, leaving today’s genetic medicine powerless against thousands of diseases. Both technologies are enormously promising, and in some cases they have already realized their promise and cured diseases. ![]() Today, this area, sometimes called genetic medicine, stands upon two technological pillars: gene therapy and gene editing. This has opened the possibility of creating therapies that not only treat previously untreatable disease but might also cure patients for life with a single treatment. Recently, scientists and doctors have gained the power to add and subtract tiles from our genomic mosaic. Every year the number of human genomes that have been sequenced increases, as does our understanding of how genes provide the instructions to make us healthy or unhealthy human beings. About 60,000 other genetic sites are significantly associated with traits and diseases such as body mass, cardiovascular disease, neurological conditions, metabolic diseases, immune responses, and many cancers. These include the cystic fibrosis transmembrane receptor, which when mutated causes cystic fibrosis, which can severely damage the lungs and other organs to the point of being life-threatening. Development, homeostasis, and reproduction aging, disease, and death-all are driven by the activity of genes.ĭoctors know of about 4,000 genes that directly cause diseases. Specific sequences of base pairs encode genes, which serve every function in our bodies. These represent the code of life and give rise to the complex phenomena that define health and disease. It is composed of base pairs, the nucleobases A, C, T, and G-the building blocks of DNA. Michael Severino, M.D.Our genome is a mosaic that has evolved over millennia. Michael Severino trades in AbbVie perch for CEO role at Flagship’s gene medicines biotech Tesseraįrom Big Pharma to little Tessera, Michael Severino rewrites his next chapter as CEO of Flagship biotechįormer AbbVie executive Severino joins Flagship-backed startup as CEO Non-CRISPR Gene Editing Platforms Make the Cut … or Avoid Making It Tessera Therapeutics Expands Leadership and Boardīiomanufacturing Parallels the Semiconductor Chip Revolution biotech startups raised $5.1 billion in the first half of 2022īRIEF-bluebird bio exec flies nest to join Tessera Therapeuticsīluebird exec spreads wings, heads over to Tessera for 'irresistible opportunity'īluebird’s regulatory chief departs two days after historic gene therapy nod to join Flagship’s Tessera Nucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure DiseasesĬan “Gene Writing” Deliver What Gene Editing Can’t?ĭespite industry-wide stock slump, Mass. Tessera Therapeutics Highlights Advancements Across its Gene Writing™ and Delivery Platforms Including Proof of Concept Data in Non-Human Primates JPM23: With preclinical gene writing data on display, Tessera CEO's spirits not dampened by California's wild weather Tessera Therapeutics to Present New Data Showcasing the Broad Potential of its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 26th Annual Meeting Tessera Therapeutics Presents New Data Demonstrating the Potential of Gene Writing™ Technology at the American Society of Gene and Cell Therapy 26th Annual Meeting ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |